Solid Biosciences Inc at Barclays Global Healthcare Conference Transcript
Hi guys, good afternoon. I'm Ellie Merle, one of the biotech analysts here at Barclays. Joining me from Barclays is my colleague Pes Wine.
We're very happy to have Solid Biosciences here with us today. A lot to talk about after, a data update yesterday. Joining us from Solid is Bocombo, President and Chief Executive Officer, and, Gabriel Brooks, Chief Medical Officer.
Thank you both so much for making the time. Maybe to begin, can you give an overview of your program, and sort of where you see it in the the DMD landscape? Yeah, first.
Thank you very much for the invitation.
Thank you, Ellie. Yeah, Solid is a precision genetic medicine company. We focus on our lead programs, Duchenne muscular dystrophy called 003, followed by Friedrich's Cetacea program. We also have multiple cardiac programs, CPPT, TNNT2. And we make a host of delivery technologies such as capsids, promoters, the dual plasmids for gene therapy delivery as well.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
